Table 3. Univariate and multivariate analysis of immune-related progression free survival.
| Variables | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Clinical variables | |||||||
| Gender (female) | 1.099 | 0.673–1.793 | 0.707 | – | – | – | |
| Age | 1.014 | 0.989–1.041 | 0.271 | – | – | – | |
| Smoking status | 1.315 | 0.653–2.648 | 0.444 | – | – | – | |
| ECOG PS | 2.053 | 1.266–3.331 | 0.004 | 2.692 | 1.488–4.872 | 0.001 | |
| Weight loss | 1.260 | 0.688–2.305 | 0.454 | – | – | – | |
| Histology (non-adenocarcinoma) | 1.570 | 0.903–2.728 | 0.110 | – | – | – | |
| Number of metastases | 1.139 | 0.902–1.439 | 0.273 | – | – | – | |
| Extrathoracic metastasis | 2.054 | 1.272–3.316 | 0.003 | 2.417 | 1.154–5.065 | 0.019 | |
| Liver metastasis | 1.204 | 0.629–2.305 | 0.575 | – | – | – | |
| Bone metastasis | 1.847 | 1.120–3.046 | 0.016 | 0.898 | 0.430–1.874 | 0.775 | |
| Molecular variables | |||||||
| Total number of gene alterations | 1.046 | 0.949–1.151 | 0.365 | – | – | – | |
| KRAS alteration | 0.854 | 0.469–1.557 | 0.607 | – | – | – | |
| TP53 alteration | 1.347 | 1.064–1.705 | 0.013 | 1.822 | 1.057–3.141 | 0.031 | |
| STK11 alteration | 1.081 | 0.889–1.314 | 0.438 | – | – | – | |
| KRAS/STK11 co-mutation | 6.029 | 1.788–20.328 | 0.004 | 5.063 | 0.410–62.479 | 0.206 | |
| STK11/TP53 co-mutation | 1.387 | 0.599–3.211 | 0.445 | – | – | – | |
| TP53/KRAS co-mutation | 0.802 | 0.232–1.990 | 0.633 | – | – | – | |
| KRAS/STK11/TP53 co-mutation | 5.088 | 1.189–21.613 | 0.027 | 5.589 | 1.239–25.221 | 0.025 | |
| FGFR1 alteration | 5.722 | 1.733–18.891 | 0.004 | 3.538 | 0.968–12.923 | 0.056 | |
| BRCA2 mutation | 6.344 | 1.873–21.486 | 0.003 | 12.302 | 2.668–56.727 | 0.001 | |
Statistically significant P values are reported in italics. CI, confidence interval; HR, hazard ratio.